On October 1, 2024, Sun Pharmaceutical Industries Ltd (Sun Pharma) and Philogen S.p.A. announced a global licensing agreement to commercialise Philogen’s cancer immunotherapy product, Fibromun (L19TNF). Fibromun is currently being tested in clinical trials for treating soft tissue sarcoma and glioblastoma.
Under the agreement, Sun Pharma will have exclusive global rights to market Fibromun, while Philogen will finish the ongoing clinical trials, seek regulatory approval, and handle manufacturing. Sun Pharma will focus on marketing the product, and both companies will share profits after commercialisation, with 45% going to Philogen and 55% to Sun Pharma. Other financial details were not disclosed.
Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, said, “Fibromun’s progress through development has been quite encouraging and it has potential to be an important option for treatment of soft-tissue sarcomas and other cancers with significant unmet medical needs. This partnership expands our clinical pipeline into oncology in alignment with our current portfolio in skin cancers. We keenly look forward to providing this treatment option globally in due course of time.”
Earlier, on May 30, 2023, Sun Pharma and Philogen announced they signed an Exclusive Distribution, License, and Supply Agreement to market the speciality product Nidlegy™ in Europe, Australia, and New Zealand. They have submitted the first Marketing Authorization Application for Nidlegy™ to the European Medicines Agency (EMA) to treat locally advanced, fully removable melanoma in the neoadjuvant setting.
Fibromun is a biopharmaceutical developed by Philogen for treating advanced soft tissue sarcoma and glioblastoma. It is made up of the L19 antibody, which is genetically linked to the Tumor Necrosis Factor (TNF). The L19 antibody specifically targets Extra Domain B of Fibronectin, a protein found in tumours but not in most healthy adult tissues.
Sun Pharmaceutical Industries Ltd is a leading global company in the speciality generics sector. It offers products in the areas of speciality, generic, and consumer healthcare. As India’s largest pharmaceutical company, it is also a major player in the US and other emerging markets worldwide. Sun Pharma’s Global Specialty portfolio, which includes innovative treatments in dermatology, ophthalmology, and onco-dermatology, contributes to more than 18% of its sales.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
